US FDA approves Lynparza to treat HRR gene-mutated mCRPC
The FDA approval was supported by results from the Phase 3 PROfound study that evaluated the efficacy and…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
21 May 20
The FDA approval was supported by results from the Phase 3 PROfound study that evaluated the efficacy and…
20 May 20
Zolgensma showed therapeutic benefit in pre-symptomatic and symptomatic SMA, including prolonged event-free survival and achievement of motor milestones
19 May 20
Enhertu is indicated for the treatment of metastatic in patients whose tumours have a HER2 mutation and with…
18 May 20
QINLOCK has been indicated for GIST in adult patients who have received prior treatment with three or more…
15 May 20
The approval is based on results of from Phase 3 ECHELON-2 trial, which showed that treatment with ADCETRIS…
14 May 20
KEYTRUDA is a humanised monoclonal antibody designed to block the interaction between PD-1 to activate the T lymphocytes
13 May 20
Moderna designed the new mRNA-1273 is an mRNA vaccine to work against SARS-CoV-2 encoding for a prefusion stabilised…
12 May 20
Lynparza is an advanced PARP inhibitor and the targeted treatment to block DNA damage response (DDR) in cells…
11 May 20
The FDA indicated Retevmo for treating a type of RET fusion-positive NSCLC, RET-mutant MTC, RET fusion-positive thyroid cancer…
11 May 20
With the regulatory approval, Entyvio becomes the only maintenance therapy for Crohn’s disease, with both intravenous and subcutaneous…